Skip to main content

Table 3 Patients with peak hs-TnT elevations

From: Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

Protective strategy

Dexrazoxane

Continuous infusion

Crossover

Patient Number

8

11

10

Peak hS-TnT > 5 ng/ml

0

0

7

Peak hs-TnT > 10 ng/ml

6

3

1